22:42:28 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandIsland
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Össur hf. är ett isländskt bolag verksamma inom hälsa - och sjukvård. Idag innehas affärsinriktning mot utvecklandet av benproteser, artros samt relaterad skadehantering. Produkterna är anpassade för olika åldrar och förutsättningar beroende på patientens svårighetsgrad. Verksamheten är etablerad globalt med störst marknad inom Europa följt av Nordamerika. Huvudkontoret ligger i Reykjavik.

Kalender

2023-03-10 Årsstämma 2023
2023-01-31 Bokslutskommuniké 2022
2022-10-25 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-03-09 Ordinarie utdelning OSSR 0.00 DKK
2022-03-08 Årsstämma 2022
2022-02-01 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-09 Ordinarie utdelning OSSR 0.00 DKK
2021-03-08 Årsstämma 2021
2021-02-02 Bokslutskommuniké 2020
2020-10-27 Kvartalsrapport 2020-Q3
2020-07-23 Kvartalsrapport 2020-Q2
2020-04-30 Kvartalsrapport 2020-Q1
2020-03-13 Ordinarie utdelning OSSR 0.15 DKK
2020-03-12 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-10-22 Kvartalsrapport 2019-Q3
2019-07-25 Kvartalsrapport 2019-Q2
2019-04-30 Kvartalsrapport 2019-Q1
2019-03-08 Ordinarie utdelning OSSR 0.14 DKK
2019-03-07 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-25 Kvartalsrapport 2018-Q2
2018-04-25 Kvartalsrapport 2018-Q1
2018-03-09 Ordinarie utdelning OSSR 0.13 DKK
2018-03-08 Årsstämma 2018
2018-02-05 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-07-25 Kvartalsrapport 2017-Q2
2017-04-27 Kvartalsrapport 2017-Q1
2017-03-10 Ordinarie utdelning OSSR 0.12 DKK
2016-03-11 Ordinarie utdelning OSSR 0.12 DKK
2016-03-10 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-07-23 Kvartalsrapport 2015-Q2
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-12 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Analytiker möte 2014
2022-04-26 08:00:00

Announcement no. 27/2022

Interim report Q1 2022

26 April 2022

Sveinn Sölvason, President and CEO, Comments:

"Continued positive development and normalization of activity levels are driving demand for Prosthetics and B&S products in our key markets. We delivered solid organic growth despite all regions being impacted by COVID-19 in the first months of the year. We are managing temporary variable supply chain related cost increases which are expected to normalize gradually. Our Power Knee, the world's first actively powered prosthetic knee, has now been successfully launched in all regions and is receiving excellent feedback. Highlighting our commitment to social responsibility and sustainable development, we published our Sustainability Report in the quarter and remain highly dedicated to providing our end-users with a Life Without Limitations."

Highlights Q1 2022
  • Sales amounted to USD 170 million. Sales growth was 10% in local currency and increased by 6% organic compared to a flat growth in local currency and an increase of 2% organic in Q1 2021.
  • Prosthetics grew by 6% organic compared to a 3% growth in Q1 2021. Bracing & Supports (B&S) increased by 5% organic compared to a decline of 1% in Q1 2021.
  • Gross profit margin was 62% in Q1 2022 compared to 64% in Q1 2021. Supply chain cost increases are expected to increase cost of goods sold by USD 13 million on a full-year basis in FY 2022 from pre-pandemic levels in FY 2019, compared to USD 10 million in FY 2021.
  • EBITDA amounted to USD 27 million in Q1 2022, and the EBITDA margin was 16% compared to 18% in Q1 2021.
  • Net profit in Q1 2022 amounted to USD 9 million or 5% of sales compared to USD 11 million or 7% of sales in Q1 2021.
  • On 24 February, Össur suspended sales to Russia due to the ongoing war and has decided to extend the suspension while the situation remains unchanged. Sales to Russia amounted to around 1% of sales in FY 2021.
  • Cash generated by operations amounted to USD 14 million or 8% of sales in Q1 2022 compared to USD 20 million or 12% of sales in the comparable period.
  • NIBD/EBITDA was 2.5x at the end of Q1 2022 within the target ratio of 2.0x-3.0x.
  • On 14 February 2022, Össur initiated a new share buyback program. The purpose of the program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Capital Allocation Policy.
  • In Q1 2022, Össur completed an acquisition with annual sales of USD 10 million.
  • The financial guidance for the full year 2022 is unchanged, 6-9% organic sales growth, 20-21% EBITDA margin before special items, 3-4% CAPEX of sales, and an effective tax rate of 23-24%.

Q1 2022 conference call details

Össur will host a conference call on 26 April 2022 at 9:00 CEST / 7:00 GMT / 3:00 ET. To participate in the call please dial:

Europe: + 45 35 44 55 77, +44 (0) 333 300 0804 or +46 (0) 8 566 426 51

The United States: + 1 631 913 1422

Iceland: +354 800 7437

The PIN CODE to access the call is 48782473#. A webcast can be followed on the Össur website: www.ossur.com/investors.  

Further information

Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com,+354 844 4759

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors

About Össur

Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people live a Life Without Limitations. A recognized "Technology Pioneer" with a rich 50-year history, Össur focuses on improving people's mobility through the delivery of innovative technologies in Prosthetics and Bracing & Supports. Significant investment in research and development have led to over 2,000 patents, award-winning designs, successful clinical outcomes, and consistently strong market positions. Össur is signatory to the UN Global Compact, UN Women's Empowerment Principles, contributes to the UN Sustainable Development Goals and became carbon neutral in 2021. Össur operates globally and employs around 4,000 employees. www.ossur.com